“Injecting Change” is a series that tracks where we are on the wave of GLP-1 agonist uptake and digs into the the vulnerabilities and opportunities various sectors face. Check out our first report on how GLP-1s are affecting the insurance industry.

Millions Are Finding the “Easy Way Out” Isn’t So Easy

When it comes to weight loss, medications (prescription or otherwise) have long been seen as the “easy way out” as compared to more “mindful” or “disciplined” options — particularly when it comes to the stigma surrounding the new class of GLP-1 drugs. But we’ve found that people taking these drugs for weight loss must put in extra thought and planning when it comes to their food and drink choices, but also to everything from celebrations to hobbies to relationships. They’re encountering social and emotional needs that they didn’t predict before taking the drugs and, in many cases, aren’t sure how to meet them.

The second report in our “Injecting Change” series dives into the challenges GLP-1 users — and those close to them — face when it comes to addressing nutritional, social, and emotional needs. We’ll also offer actionable thought starters for brands and marketers to set themselves up for success by helping meet the needs of the growing number of GLP-1 users and their loved ones.

About the Series

Like AI, GLP-1 agonists are an innovation with the potential to impact so many industries that affect our lives, from QSR to wellness to impulse shopping. With nearly half a billion dollars in category ad spend last year and a market predicted to exceed $100 billion by 2030, we’re at the beginning of a revolution that could leave almost no brand untouched.

Horizon Media’s WHY Group has set out to understand the impact of this category of drugs on a variety of industries in order to help our clients future-proof themselves by innovating with instead of fighting against the upheaval. Powered by our Finger on the Pulse panel and social and cultural intelligence, each report in our Injecting Change series will track where we are on the wave of GLP-1 agonist uptake and elaborate on the vulnerabilities and opportunities various sectors face. We’ll also give actionable steps we can take to help you navigate this period of change via research, media, and marketing.

Check out the first report in our series here: Injecting Change: Weighing the Future of Insurance in the Age of Ozempic